A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma

on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

The efficacy and safety of lenalidomide (LEN) consolidation therapy and subsequent LEN maintenance therapy after high-dose therapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in patients with newly diagnosed symptomatic multiple myeloma (MM). Forty-one patients were enrolled and received high-dose dexamethasone (DEX) therapy as an initial induction. The patients who did not respond to the DEX therapy were further treated with four cycles of bortezomib plus DEX (BD) induction therapy. For patients who responded to BD, PBSC harvesting was scheduled following high-dose cyclophosphamide and filgrastim administration. After PBSC harvesting, high-dose chemotherapy of melphalan with auto-PBSCT was performed. One hundred days after auto-PBSCT, patients received consolidation therapy consisting two cycles of LEN plus low-dose DEX (Ld) and LEN maintenance therapy. Only one death occurred during mobilization therapy, but the protocol developed in this study was considered generally safe to provide. Overall response rates after consolidation and maintenance therapies were 73.7% and 81.6%, respectively. Two-year progression-free survival and overall survival were 76.3% and 92.1%, respectively. These observations suggest that LEN consolidation and maintenance therapy are effective and safe, and provide favorable response rates in patients with MM.

元の言語英語
ページ(範囲)107-114
ページ数8
ジャーナルInternational journal of hematology
109
発行部数1
DOI
出版物ステータス出版済み - 1 22 2019

Fingerprint

Multiple Myeloma
Peripheral Blood Stem Cell Transplantation
Dexamethasone
Therapeutics
lenalidomide
Melphalan
Cyclophosphamide
Disease-Free Survival
Safety
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Hematology

これを引用

A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma. / on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT).

:: International journal of hematology, 巻 109, 番号 1, 22.01.2019, p. 107-114.

研究成果: ジャーナルへの寄稿記事

on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT). / A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma. :: International journal of hematology. 2019 ; 巻 109, 番号 1. pp. 107-114.
@article{b996599c1c604fa4b3f0a9265b44743a,
title = "A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma",
abstract = "The efficacy and safety of lenalidomide (LEN) consolidation therapy and subsequent LEN maintenance therapy after high-dose therapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in patients with newly diagnosed symptomatic multiple myeloma (MM). Forty-one patients were enrolled and received high-dose dexamethasone (DEX) therapy as an initial induction. The patients who did not respond to the DEX therapy were further treated with four cycles of bortezomib plus DEX (BD) induction therapy. For patients who responded to BD, PBSC harvesting was scheduled following high-dose cyclophosphamide and filgrastim administration. After PBSC harvesting, high-dose chemotherapy of melphalan with auto-PBSCT was performed. One hundred days after auto-PBSCT, patients received consolidation therapy consisting two cycles of LEN plus low-dose DEX (Ld) and LEN maintenance therapy. Only one death occurred during mobilization therapy, but the protocol developed in this study was considered generally safe to provide. Overall response rates after consolidation and maintenance therapies were 73.7{\%} and 81.6{\%}, respectively. Two-year progression-free survival and overall survival were 76.3{\%} and 92.1{\%}, respectively. These observations suggest that LEN consolidation and maintenance therapy are effective and safe, and provide favorable response rates in patients with MM.",
author = "{on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)} and Fuchida, {Shin ichi} and Kazutaka Sunami and Morio Matsumoto and Hirokazu Okumura and Tohru Murayama and Toshihiro Miyamoto and Eichi Otsuka and Naohito Fujishima and Tohru Izumi and Shigehisa Tamaki and Yasushi Hiramatsu and Yoshiaki Kuroda and Chihiro Shimazaki and Koichi Akashi and Mine Harada",
year = "2019",
month = "1",
day = "22",
doi = "10.1007/s12185-018-2543-y",
language = "English",
volume = "109",
pages = "107--114",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma

AU - on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)

AU - Fuchida, Shin ichi

AU - Sunami, Kazutaka

AU - Matsumoto, Morio

AU - Okumura, Hirokazu

AU - Murayama, Tohru

AU - Miyamoto, Toshihiro

AU - Otsuka, Eichi

AU - Fujishima, Naohito

AU - Izumi, Tohru

AU - Tamaki, Shigehisa

AU - Hiramatsu, Yasushi

AU - Kuroda, Yoshiaki

AU - Shimazaki, Chihiro

AU - Akashi, Koichi

AU - Harada, Mine

PY - 2019/1/22

Y1 - 2019/1/22

N2 - The efficacy and safety of lenalidomide (LEN) consolidation therapy and subsequent LEN maintenance therapy after high-dose therapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in patients with newly diagnosed symptomatic multiple myeloma (MM). Forty-one patients were enrolled and received high-dose dexamethasone (DEX) therapy as an initial induction. The patients who did not respond to the DEX therapy were further treated with four cycles of bortezomib plus DEX (BD) induction therapy. For patients who responded to BD, PBSC harvesting was scheduled following high-dose cyclophosphamide and filgrastim administration. After PBSC harvesting, high-dose chemotherapy of melphalan with auto-PBSCT was performed. One hundred days after auto-PBSCT, patients received consolidation therapy consisting two cycles of LEN plus low-dose DEX (Ld) and LEN maintenance therapy. Only one death occurred during mobilization therapy, but the protocol developed in this study was considered generally safe to provide. Overall response rates after consolidation and maintenance therapies were 73.7% and 81.6%, respectively. Two-year progression-free survival and overall survival were 76.3% and 92.1%, respectively. These observations suggest that LEN consolidation and maintenance therapy are effective and safe, and provide favorable response rates in patients with MM.

AB - The efficacy and safety of lenalidomide (LEN) consolidation therapy and subsequent LEN maintenance therapy after high-dose therapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in patients with newly diagnosed symptomatic multiple myeloma (MM). Forty-one patients were enrolled and received high-dose dexamethasone (DEX) therapy as an initial induction. The patients who did not respond to the DEX therapy were further treated with four cycles of bortezomib plus DEX (BD) induction therapy. For patients who responded to BD, PBSC harvesting was scheduled following high-dose cyclophosphamide and filgrastim administration. After PBSC harvesting, high-dose chemotherapy of melphalan with auto-PBSCT was performed. One hundred days after auto-PBSCT, patients received consolidation therapy consisting two cycles of LEN plus low-dose DEX (Ld) and LEN maintenance therapy. Only one death occurred during mobilization therapy, but the protocol developed in this study was considered generally safe to provide. Overall response rates after consolidation and maintenance therapies were 73.7% and 81.6%, respectively. Two-year progression-free survival and overall survival were 76.3% and 92.1%, respectively. These observations suggest that LEN consolidation and maintenance therapy are effective and safe, and provide favorable response rates in patients with MM.

UR - http://www.scopus.com/inward/record.url?scp=85054603110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054603110&partnerID=8YFLogxK

U2 - 10.1007/s12185-018-2543-y

DO - 10.1007/s12185-018-2543-y

M3 - Article

C2 - 30284685

AN - SCOPUS:85054603110

VL - 109

SP - 107

EP - 114

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -